Blog Archives

ATSJournals Publication – Mitigation of Ventilator-Induced Diaphragm Atrophy by Transvenous Phrenic Nerve Stimulation

The top-ranked American Journal of Respiratory and Critical Care Medicine has published on-line a pre-clinical research study demonstrating  that the Lungpacer therapy mitigated ventilator-induced diaphragm atrophy in pigs that were sedated and ventilated in ICU-like conditions for 60 hours. Mitigation

Posted in News

Steven Reynolds, MD to Present Data on the PACER Trial for Lungpacer Medical’s Diaphragm Pacing Catheter in Mechanically Ventilated Patients

BURNABY, British Columbia, May 18, 2016 /PRNewswire/ — Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today that Steven Reynolds, MD will be presenting data related to the recently completed Phrenic Activation for Enhanced Respiration (PACER) feasibility

Posted in News

Lungpacer Medical, Inc. Receives Expedited Access Pathway Designation from FDA for the Lungpacer Diaphragm Pacing System

Burnaby, British Columbia, Canada – May 11, 2016 – Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today that it has received Expedited Access Pathway (EAP) designation from the U.S. Food and Drug Administration

Posted in News

Lungpacer Medical, Inc. Announces Start of First-in-Human Early Feasibility Trial

BURNABY, British Columbia, Oct. 21, 2015 /PRNewswire/ — Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today the enrollment of the first patients in the Phrenic ACtivation for Enhanced Respiration (PACER) early feasibility trial.

Posted in News

Lungpacer Medical, Inc. to Present at Jefferies 2015 Global Healthcare Conference

External Link: Lungpacer Medical, Inc. to Present at Jefferies 2015 Global Healthcare Conference

Posted in News

Steve Reynolds, MD, to Present Encouraging Preclinical Results with Lungpacer Medical’s Catheter-based Diaphragm Pacing System

External Link: Steve Reynolds, MD, to Present Encouraging Preclinical Results with Lungpacer Medical’s Catheter-based Diaphragm Pacing System

Posted in News

Lungpacer Medical Inc participating at Innovations in Neuromodulation

External Link: Neuromodulation Innovation – and Reimbursement, A Leadership Summit on the Development of Emerging Therapies

Posted in News

Lungpacer named a “2015 Ready to Rocket Life Science Company”

Lungpacer named a “2015 Ready to Rocket Life Science Company” Ready to Rocket is a unique business recognition list that profiles British Columbia technology companies with the greatest potential for revenue growth. Each year, based on analysis of trends that

Posted in News

Lungpacer expands into new location

SFU spinout Lungpacer Medical Inc. welcomed nearly 100 guests on Dec. 11 to its new 6,500-sq.-ft. Burnaby premises, which are 3 1/2 times larger than the SFU Neurokinesiology Laboratory location where the company originated. Since its establishment in 2009, Lungpacer has grown from seven

Posted in News

CIHR Proof-of-Principle Grant for First-in-Human Trials at Royal Columbian Hospital

Dr. Steve Reynolds, head of Critical Care and infectious diseases specialist at Royal Columbian Hospital, and Dr. Andy Hoffer, founder of Lungpacer Medical Inc., are collaborating to improve how intensive care units provide respiratory support for their sickest patients. A $160,000 proof-of-principle Phase

Posted in News
News